<p><em>旗舰与 GSK 框架合作下的首次可行性协议</em></p>
<p><em>协议将利用 ProFound 和 Quotient 的平台技术来发现和验证呼吸系统和肝脏疾病的新治疗方法</em></p>
<p>, /PRNewswire/ -- 旗舰开创（Flagship Pioneering）是一家致力于变革性平台和产品的科学创新引擎，今天宣布 ProFound Therapeutics 和 Quotient Therapeutics 已与 GSK 签署了单独的可行性协议，以发现和验证呼吸系统和肝脏疾病的新靶点和治疗方法。这是旗舰与 GSK 框架合作下签署的首个以公司为中心的协议，旨在将 GSK 的疾病领域专业知识和开发能力与旗舰的生物平台公司生态系统相结合，包括其新颖的模式和技术。</p>
<p>&#34;旗舰开创与 GSK 有着共同的使命，通过将创新的新技术与深厚的药物开发专业知识相结合，加速为最需要帮助的患者开发突破性药物，&#34;旗舰开创的管理合伙人 Paul Biondi 表示。&#34;这些协议将两种开创性的方法结合在一起，以推进呼吸系统和肝脏疾病的创新治疗，并识别可能改变疾病进程的新颖和差异化的靶点。&#34;</p>
<p><strong>利用扩展的人类蛋白组推进呼吸系统疾病的新药物</strong></p>
<p>ProFound 将利用其 ProFoundry™平台，该平台结合了最先进的蛋白质检测技术、针对性的高通量功能验证方法和先进的计算工具，从扩展的人类蛋白组中挖掘出丰富的差异化潜在蛋白药物和药物靶点，这是一组由人类基因组编码的先前未被识别的蛋白质。通过两项单独的协议，ProFound 将推进基础发现，以表征与慢性阻塞性肺病（COPD）和特发性肺纤维化（IPF）强相关的新蛋白，并检查它们在这些疾病中的治疗相关性。</p>
<p><strong>利用体细胞基因组学解锁呼吸系统和肝脏疾病的新疗法</strong></p>
<p>Quotient 的尖端体细胞基因组学平台有潜力通过研究患者中存在的自然获得的遗传多样性，解锁任何疾病的新治疗策略。通过三项单独的协议，Quotient 将利用其体细胞基因组学技术识别导致疾病的药物靶点，这些靶点有潜力创造 COPD、IPF 和代谢功能障碍相关脂肪肝炎（MASH）的突破性药物。</p>
<p>根据协议条款，如果 GSK 选择进一步合作，ProFound 和 Quotient 将通过关键的临床前活动推进各自的项目，之后 GSK 将拥有将项目推进至临床研究的独占选择权。</p>
<p><strong>关于 ProFound™ Therapeutics</strong> ProFound™ Therapeutics 正在发现隐藏在扩展人类蛋白组中的蛋白质，以揭示新药物和药物靶点，为多种疾病生产首创药物。该公司的 ProFoundry™平台利用最先进的蛋白质检测技术系统地识别和验证新蛋白，并剖析其治疗潜力。其结果是一个不断扩展的数据库，包含数以万计的新蛋白，包括它们的连接性、功能性以及在健康和疾病中的作用。ProFound Therapeutics 成立于 2020 年，由旗舰开创创立。有关更多信息，请访问 www.profoundtx.com。</p>
<p><strong>关于 Quotient Therapeutics</strong> Quotient Therapeutics 开发突破性药物，基于患者中存在的自然体细胞遗传多样性。通过我们的综合体细胞基因组学和计算技术，我们获得了对导致疾病的药物靶点的无偏见、前所未有的解析，这些靶点被我们用来设计和开发首创疗法。通过这一点，我们正在通过广泛的内部和合作项目管道，开创生物制药研究和开发的新常态。我们于 2022 年由旗舰开创成立。有关更多信息，请访问 www.quotient-tx.com。</p>
<p><strong>关于旗舰开创和开创药物</strong> 旗舰开创发明并建立平台公司，每个公司都有潜力开发多种产品，以改变人类健康、可持续性等。自 2000 年成立以来，旗舰已创办并培育了 100 多项科学事业，截至 2024 年 7 月的最新融资轮，其管理资产达 140 亿美元。目前，旗舰生态系统包括 40 多家公司，包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
<p>开创药物是旗舰开创的内部药物开发单位，致力于构思和开发广泛的改变患者生活的治疗组合，基于旗舰的创新平台。开创药物利用其团队的药物开发专业知识以及旗舰多个科学平台的力量，探索和识别新的产品概念，然后与旗舰的生物平台公司共同推进。在旗舰的创新供应链合作伙伴关系中，开创药物与外部合作伙伴合作，将其独特的方法应用于合作伙伴的研发优先事项。这些合作伙伴关系是高度共创的战略联盟，通过将涵盖药物发现、开发和生产全范围的合作伙伴聚集在一起，加速治疗创新。</p>
<p><strong>媒体联系人：</strong></p>
<p>旗舰开创</p>
<p>[email protected]</p>
<p>来源 旗舰开创</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy"/></p>

葛兰素史克

<p>旗舰先锋公司（Flagship Pioneering）宣布与 ProFound Therapeutics 和 Quotient Therapeutics 达成新协议，旨在与葛兰素史克（GSK）合作。这些协议旨在利用 ProFound 和 Quotient 的平台技术发现和验证针对呼吸系统和肝脏疾病的新疗法。如果成功，GSK 可能会将这些项目推进到临床研究阶段。ProFound 将专注于慢性阻塞性肺病（COPD）和特发性肺纤维化（IPF）的蛋白质检测，而 Quotient 将使用体细胞基因组学技术针对 COPD、IPF 和 MASH</p>

<p><em>First feasibility agreements under Flagship and GSK framework collaboration</em></p>
<div class="lb-trans"><p><em>旗舰与 GSK 框架合作下的首次可行性协议</em></p>
</div><p><em>Agreements will utilize ProFound's and Quotient's platform technologies to discover and validate novel treatments for respiratory and liver diseases</em></p>
<div class="lb-trans"><p><em>协议将利用 ProFound 和 Quotient 的平台技术来发现和验证呼吸系统和肝脏疾病的新治疗方法</em></p>
</div><p>, /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced that ProFound Therapeutics and Quotient Therapeutics have entered into separate feasibility agreements with GSK to discover and validate novel targets and therapeutic approaches in respiratory and liver diseases. These are the first company-focused agreements signed under the framework collaboration between Flagship and GSK to combine GSK's disease area expertise and development capabilities with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 旗舰开创（Flagship Pioneering）是一家致力于变革性平台和产品的科学创新引擎，今天宣布 ProFound Therapeutics 和 Quotient Therapeutics 已与 GSK 签署了单独的可行性协议，以发现和验证呼吸系统和肝脏疾病的新靶点和治疗方法。这是旗舰与 GSK 框架合作下签署的首个以公司为中心的协议，旨在将 GSK 的疾病领域专业知识和开发能力与旗舰的生物平台公司生态系统相结合，包括其新颖的模式和技术。</p>
</div><p>&#34;Flagship Pioneering and GSK have a shared mission to accelerate the development of breakthrough medicines for patients with the greatest unmet needs by combining innovative new technologies with deep drug development expertise,&#34; said Paul Biondi, Managing Partner, Flagship Pioneering. &#34;These agreements bring together two pioneering approaches to advance innovative treatments for respiratory and liver diseases, and to identify novel and differentiated targets that may alter the course of disease.&#34;</p>
<div class="lb-trans"><p>&#34;旗舰开创与 GSK 有着共同的使命，通过将创新的新技术与深厚的药物开发专业知识相结合，加速为最需要帮助的患者开发突破性药物，&#34;旗舰开创的管理合伙人 Paul Biondi 表示。&#34;这些协议将两种开创性的方法结合在一起，以推进呼吸系统和肝脏疾病的创新治疗，并识别可能改变疾病进程的新颖和差异化的靶点。&#34;</p>
</div><p><strong>Tapping the expanded human proteome to advance novel medicines for respiratory diseases</strong></p>
<div class="lb-trans"><p><strong>利用扩展的人类蛋白组推进呼吸系统疾病的新药物</strong></p>
</div><p>ProFound will leverage its ProFoundry™ Platform, which combines state-of-the-art protein detection technologies, targeted high-throughput functional validation methods, and advanced computational tools, to unearth a rich source of differentiated potential protein drugs and drug targets from the expanded human proteome, a vast set of previously unrecognized proteins encoded by the human genome. Through two separate agreements, ProFound will advance foundational discoveries to characterize novel proteins with strong genetic associations with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) and examine their therapeutic relevance for these diseases.</p>
<div class="lb-trans"><p>ProFound 将利用其 ProFoundry™平台，该平台结合了最先进的蛋白质检测技术、针对性的高通量功能验证方法和先进的计算工具，从扩展的人类蛋白组中挖掘出丰富的差异化潜在蛋白药物和药物靶点，这是一组由人类基因组编码的先前未被识别的蛋白质。通过两项单独的协议，ProFound 将推进基础发现，以表征与慢性阻塞性肺病（COPD）和特发性肺纤维化（IPF）强相关的新蛋白，并检查它们在这些疾病中的治疗相关性。</p>
</div><p><strong>Harnessing somatic genomics to unlock novel therapies for respiratory and liver diseases</strong></p>
<div class="lb-trans"><p><strong>利用体细胞基因组学解锁呼吸系统和肝脏疾病的新疗法</strong></p>
</div><p>Quotient's cutting-edge Somatic Genomics platform has the potential to unlock new therapeutic strategies across any disease by studying the natural, acquired genetic diversity present in patients. Through three separate agreements, Quotient will use its somatic genomics technology to identify disease-causal drug targets that have the potential to create breakthrough medicines for COPD, IPF and Metabolic Dysfunction-Associated Steatohepatitis (MASH).</p>
<div class="lb-trans"><p>Quotient 的尖端体细胞基因组学平台有潜力通过研究患者中存在的自然获得的遗传多样性，解锁任何疾病的新治疗策略。通过三项单独的协议，Quotient 将利用其体细胞基因组学技术识别导致疾病的药物靶点，这些靶点有潜力创造 COPD、IPF 和代谢功能障碍相关脂肪肝炎（MASH）的突破性药物。</p>
</div><p>Under the terms of the agreements, if GSK elects to progress into a further collaboration, ProFound and Quotient will advance their respective programs through key preclinical activities, after which GSK will have the exclusive option to advance the programs into clinical studies.</p>
<div class="lb-trans"><p>根据协议条款，如果 GSK 选择进一步合作，ProFound 和 Quotient 将通过关键的临床前活动推进各自的项目，之后 GSK 将拥有将项目推进至临床研究的独占选择权。</p>
</div><p><strong>About ProFound™ Therapeutics</strong> ProFound™ Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel drugs and drug targets, producing first-in-class medicines for a multitude of diseases. The company's ProFoundry™ Platform uses state-of-the-art protein detection technologies to systematically identify and validate novel proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 by Flagship Pioneering. For more information, please visit www.profoundtx.com.</p>
<div class="lb-trans"><p><strong>关于 ProFound™ Therapeutics</strong> ProFound™ Therapeutics 正在发现隐藏在扩展人类蛋白组中的蛋白质，以揭示新药物和药物靶点，为多种疾病生产首创药物。该公司的 ProFoundry™平台利用最先进的蛋白质检测技术系统地识别和验证新蛋白，并剖析其治疗潜力。其结果是一个不断扩展的数据库，包含数以万计的新蛋白，包括它们的连接性、功能性以及在健康和疾病中的作用。ProFound Therapeutics 成立于 2020 年，由旗舰开创创立。有关更多信息，请访问 www.profoundtx.com。</p>
</div><p><strong>About Quotient Therapeutics</strong> Quotient Therapeutics develops breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our integrated somatic genomics and computational technologies, we gain unbiased, unprecedented resolution into disease-causal drug targets that we leverage to design and develop first-in-class therapies. With this, we are forging a new status quo for biopharma research and development through a broad pipeline of internal and partnered programs. We were founded by Flagship Pioneering in 2022. For more information, visit www.quotient-tx.com.</p>
<div class="lb-trans"><p><strong>关于 Quotient Therapeutics</strong> Quotient Therapeutics 开发突破性药物，基于患者中存在的自然体细胞遗传多样性。通过我们的综合体细胞基因组学和计算技术，我们获得了对导致疾病的药物靶点的无偏见、前所未有的解析，这些靶点被我们用来设计和开发首创疗法。通过这一点，我们正在通过广泛的内部和合作项目管道，开创生物制药研究和开发的新常态。我们于 2022 年由旗舰开创成立。有关更多信息，请访问 www.quotient-tx.com。</p>
</div><p><strong>About Flagship Pioneering and Pioneering Medicines</strong> Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health.</p>
<div class="lb-trans"><p><strong>关于旗舰开创和开创药物</strong> 旗舰开创发明并建立平台公司，每个公司都有潜力开发多种产品，以改变人类健康、可持续性等。自 2000 年成立以来，旗舰已创办并培育了 100 多项科学事业，截至 2024 年 7 月的最新融资轮，其管理资产达 140 亿美元。目前，旗舰生态系统包括 40 多家公司，包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
</div><p>Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Within Flagship's Innovation Supply Chain partnerships, Pioneering Medicines works with external collaborators to apply its unique approach to partners' R&amp;D priorities. These partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production.</p>
<div class="lb-trans"><p>开创药物是旗舰开创的内部药物开发单位，致力于构思和开发广泛的改变患者生活的治疗组合，基于旗舰的创新平台。开创药物利用其团队的药物开发专业知识以及旗舰多个科学平台的力量，探索和识别新的产品概念，然后与旗舰的生物平台公司共同推进。在旗舰的创新供应链合作伙伴关系中，开创药物与外部合作伙伴合作，将其独特的方法应用于合作伙伴的研发优先事项。这些合作伙伴关系是高度共创的战略联盟，通过将涵盖药物发现、开发和生产全范围的合作伙伴聚集在一起，加速治疗创新。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系人：</strong></p>
</div><p>Flagship Pioneering</p>
<div class="lb-trans"><p>旗舰开创</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Flagship Pioneering</p>
<div class="lb-trans"><p>来源 旗舰开创</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NE28922&amp;Transmission_Id=202511200630PR_NEWS_USPR_____NE28922&amp;DateId=20251120"/></p>

06:30 ET
			
			
				Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK

旗舰开创公司宣布在与 GSK 的合作框架下，与 ProFound Therapeutics 和 Quotient Therapeutics 达成新协议